Martin H. Voss, MD | Authors


Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC

November 16, 2019

Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.